CTRI/2014/08/004827CompletedPhase 3
A Randomized, Double Blind, Double Dummy, Comparative, Prospective, Multicenter, Parallel Study to assess Efficacy, Safety and Tolerability of Fixed Dose Combination of Teneligliptin and Metformin Tablet Compared with Metformin monotherapy in Adult Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Alone.
Glenmark Pharmaceuticals Ltd0 sites378 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 378
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. Patients age >=18 and <=65 years inclusive of either sex willing to give their written informed consent and comply with the protocol requirements.
- •2. Patients with Type 2 Diabetes Mellitus who have been treated with upto 1 gram per day of Metformin monotherapy for at least 3 months prior to screening and having inadequate glycaemic control [Glycosylated Haemoglobin (HbA1c) levels of >7% to <= 9%].
Exclusion Criteria
- •1. Pregnant or lactating women.
- •2. Female Patient of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study therapy and for 4 weeks after the end of study therapy.
- •3. Patient with Type 1 diabetes mellitus or secondary form of diabetes.
- •4. Patients with known hypersensitivity to any of the components of the formulation.
- •5. Known cases of diabetic nephropathy, diabetic ketoacidosis, diabetic coma, hyperglycemia hyperosmolar state, retinopathy, neuropathy or other diabetic complications of sufficient severity to require treatment like severe Peripheral Neuropathy, Symptomatic Orthostatic Hypotension, Urinary Retention, Foot ulcers, or Gastric Stasis.
- •6. Patients who have a recent history or who are currently known to abuse alcohol or drugs.
- •7. Patients with clinically significant renal, hepatic, or cerebrovascular disease, known pituitary or gastric dysfunction, malignancy, thyroid dysfunction, chronic uncontrolled systemic diseases like asthma, collagen disorders, severe infection etc. or any other medical illness that may affect patient safety or difficult to evaluate the efficacy of the product.
- •8. Patients receiving treatment with systemic corticosteroids.
- •9. Patients who have participated in any clinical trial in the past 1 month.
- •10. Any other condition that in the opinion of the Investigator that does not justify the patientâ??s participation in the study.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Comparison of Safety and Efficacy between Retapamulin Ointment, 1% and Oral Linezolid in the treatment of Secondarily-Infected Traumatic Lesions and Impetigo.secondarily-infected traumatic lesions (SITLexcluding abscesses) or impetigo dueto methicillin-resistant Staphylococcus aureus (MRSAMedDRA version: 19.1Level: PTClassification code 10021531Term: ImpetigoSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004886-98-Outside-EU/EEAGlaxoSmithKline500
Active, not recruiting
Not Applicable
Study to compare the effects of Z7200 And Symbicort® Turbohaler on respiratory imaging parameters in asthmatic patients.AsthmaMedDRA version: 17.0Level: LLTClassification code 10049106Term: Asthma chronicSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.0Level: LLTClassification code 10003565Term: AsthmaticSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 17.0Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-002151-26-BEZambon Spa
Active, not recruiting
Not Applicable
Study To compare Umeclidinium/Vilanterol combination with Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Continue To have Symptoms on Tiotropium.Chronic Obstructive Pulmonary Disease (COPD) which may also be called emphysema or chronic bronchitisMedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2012-005007-41-EEGlaxoSmithKline Research & Development Limited666
Active, not recruiting
Phase 1
Study To compare Umeclidinium/Vilanterol combination with Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Continue To have Symptoms on Tiotropium.Chronic Obstructive Pulmonary Disease (COPD) which may also be called emphysema or chronic bronchitisMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2012-005007-41-NLGlaxoSmithKline Research & Development Limited739
Withdrawn
Phase 3
A Randomised, Double Blind, Double Dummy, Parallel Group Study Comparing UMEC/VI (A Fixed Combination Of Umeclidinium and Vilanterol) With Tiotropium In COPD Subjects Who Continue To Have Symptoms on Tiotropium (DB2116960)NL-OMON38952GlaxoSmithKline BV45